Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1416326
This article is part of the Research Topic Exploring the New Biomarkers and Clinical Indicators for Diabetes: Insights from Real-World Studies View all 18 articles

Changes in serum uteroglobin level in type 2 diabetes mellitus patients

Provisionally accepted
Joung Youl Lim Joung Youl Lim 1Sang-Hyeon Ju Sang-Hyeon Ju 2Ji Min Kim Ji Min Kim 3Hyon-Seung Yi Hyon-Seung Yi 1Ju Hee Lee Ju Hee Lee 1Hyun Jin Kim Hyun Jin Kim 1Bon Jeong Ku Bon Jeong Ku 1*Kyong Hye Joung Kyong Hye Joung 3*
  • 1 Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon, Republic of Korea
  • 2 Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
  • 3 Department of Endocrinology and Metabolism, Chungnam National University Sejong Hospital, Sejong, Republic of Korea

The final, formatted version of the article will be published soon.

    Uteroglobin is a multifunctional protein with anti-inflammatory properties. Studies have revealed the importance of inflammation in type 2 diabetes mellitus (T2D) pathogenesis. Here, we investigated the relationship between uteroglobin and T2D.We performed diagnostic tests for diabetes in subjects who had not been diagnosed with or treated for T2D. We established three groups, containing those with normal glucose tolerance (NGT), prediabetes and T2D, consisting of 80 people each, and compared their uteroglobin levels. In addition, 28 patients newly diagnosed with T2D were treated with metformin for 12 weeks, and 63 patients newly diagnosed with dyslipidaemia during the treatment for T2D were treated with statin for 12 weeks.This study showed that uteroglobin levels were significantly lower in prediabetes and T2D groups than in the NGT group. Uteroglobin levels were not significantly correlated with other metabolic parameters, except BMI, HOMA-β and eGFR. In the group treated with metformin or statin, uteroglobin levels increased after treatment compared to before treatment.Uteroglobin is a sensitive factor that was decreased even in prediabetes and increased upon treatment with drugs with anti-inflammatory effects. Uteroglobin is a potential early biomarker that reflects a chronic inflammatory condition in T2D.

    Keywords: Uteroglobin, type 2 diabetes mellitus, Dyslipidaemia, Metformin, statin

    Received: 12 Apr 2024; Accepted: 09 Sep 2024.

    Copyright: © 2024 Lim, Ju, Kim, Yi, Lee, Kim, Ku and Joung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Bon Jeong Ku, Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon, Republic of Korea
    Kyong Hye Joung, Department of Endocrinology and Metabolism, Chungnam National University Sejong Hospital, Sejong, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.